Researcher
Piet Ost
- Keywords:Radiotherapy, Prostate Cancer
- Disciplines:Cancer therapy, Palliative care and end-of-life care, Urology, Radiation therapy
Affiliations
- Department of Human Structure and Repair (Department)
Member
From1 Oct 2018 → Today - Dean's Office of the Faculty of Medicine and Health Sciences (Administrative office)
Member
From1 Jul 2012 → 30 Sep 2012 - Department of Radiation oncology and experimental cancer research (Department)
Member
From1 Nov 2008 → 30 Sep 2018
Projects
1 - 10 of 14
- Omics analysis in liquid biopsy samples of advanced tumoursFrom1 Nov 2023 → TodayFunding: BOF - doctoral mandates
- Digital pathology as a proxy for molecular profiling of prostate tumorsFrom1 Oct 2022 → TodayFunding: BOF - projects
- Detection of biomarkers to reduce radiation-induced toxicities and improve clinical outcomes, with emphasis on the role of unintended dose.From1 Sep 2022 → 31 Aug 2023Funding: Nonprofit institution or equivalents
- Kom op tegen Kanker: "ProBio-mHSPC: an outcome-adaptive, multi-arm, open-label, randomized biomarkerdriven trial in patients with de novo metastatic hormone-sensitive prostate cancer"From1 Apr 2022 → TodayFunding: Nonprofit institution or equivalents
- Study of the molecular mechanisms of metastasis in prostate cancer.From1 Oct 2021 → 31 Jan 2022Funding: BOF - doctoral mandates
- ProBio: an outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker-driven trial in patients with metastatic castration-resistant prostate cancerFrom1 Feb 2020 → 31 Jan 2024Funding: Nonprofit institution or equivalents
- A data-driven integrative framework for the identification of cancer driver pathways and their mode of action.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- CHEckpoint inhibition in combination with an immunoboost of External body adiotherapy in oligometastatic or oligoprogressive Solid tumors: CHEERS-trialFrom1 Jul 2018 → 30 Jun 2023Funding: Nonprofit institution or equivalents
- Effect and process evaluation of an intervention program on physical activity and sedentary behavior in castrate resistant prostate cancer patientsFrom1 Oct 2017 → 30 Sep 2022Funding: FWO fellowships
- PEACE V: a randomized phase III trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)From1 Jan 2017 → 31 Oct 2021Funding: BOF - Doctoral projects
Publications
161 - 170 of 242
- Practice patterns compared with evidence-based strategies for the management of androgen deprivation therapy-induced side effects in prostate cancer patients : results of a European web-based survey
Authors: Renée Bultijnck, Cristian Surcel, Guillaume Ploussard, Alberto Briganti, Pieter De Visschere, Jurgen Fütterer, Pirus Ghadjar, Gianluca Giannarini, Hendrik Isbarn, Christophe Massard, et al.
Pages: 514 - 521 - Genomic features of lung-recurrent hormone-sensitive prostate cancer
Authors: Nicolette M. Fonseca, Cameron Herberts, Sarah W.S. Ng, Nicolaas Lumen, Elie Ritch, Andrew J. Murtha, Cecily Q. Bernales, Elena Schönlau, Lisa Moris, Matti Annala, et al.
- Reply from authors re: Vincent Khoo. Is there another bite of the cherry? The case for radical local therapy for oligometastatic disease in prostate cancer. Eur Urol 2016;69:13-4 Oligometastatic prostate cancer: more than just cherry-picking?
Authors: Barbara Alicja Jereczek-Fossa, Piet Ost, Gert De Meerleer
Pages: 14 - 15 - Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer
Authors: Sarah Buelens, Elise De Bleser, Wesley Verla, Piet Ost, Kathia De Man, CHLOE STANDAERT, Nicolaas Lumen
Pages: 2565 - 2571 - To prospectively compare F18-choline PET/CT and axial skeleton MRI for the detection of bone metastases in patients with biochemically recurrent prostate cancer (PCa)Volume: 13
Authors: Piet Ost, Wouter Huysse, Louke Delrue, Gert De Meerleer, Filip De Vos, Valérie Fonteyne, Bieke Lambert
Pages: 132 - 133 - Detection, localisation and exclusion of high grade prostate cancer with multiparametric MRI: correlation with radical prostatectomy histopathology
Authors: Pieter De Visschere, ALEXANDRA DE POTTER, Gert De Meerleer, Nicolaas Lumen, Valérie Fonteyne, Piet Ost, Willem Oosterlinck
Number of pages: 1 - Nonsurgical salvage local therapies for radiorecurrent prostate cancer : a systematic review and meta-analysis
Authors: Gianluca Ingrosso, Carlotta Becherini, Andrea Lancia, Saverio Caini, Piet Ost, Giulio Francolini, Morten Hoyer, Marta Bottero, Alberto Bossi, Thomas Zilli, et al.
Pages: 183 - 197 - Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. 'Gotta catch 'em all' or do we? Pokemet approach to metastatic prostate cancer. Eur Urol 2017;72:1U+20133
Authors: Alison C Tree, Shankar Siva, Piet Ost
Pages: E66 - E67 - Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperbert, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30
Authors: Piet Ost, Alberto Bossi, Gert De Meerleer
Pages: e33 - e33 - Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes : a systematic review of the role of stereotactic body radiotherapy
Authors: Elisabetta Ponti, Andrea Lancia, Piet Ost, Fabio Trippa, Luca Triggiani, Beatrice Detti, Gianluca Ingrosso
Pages: 538 - 544